培美曲塞治疗肺癌临床疗效观察 |
| |
引用本文: | 魏玲,孙三元,于大海,孙丽.培美曲塞治疗肺癌临床疗效观察[J].四川医学,2011,32(9):1420-1421. |
| |
作者姓名: | 魏玲 孙三元 于大海 孙丽 |
| |
作者单位: | 徐州市中心医院肿瘤内科,放疗科,江苏徐州221009 |
| |
摘 要: | 目的评价培美曲塞治疗复发性晚期肺癌患者的近期疗效及不良反应。方法选择27例经病理学或细胞学确诊的复发性晚期非小细胞肺癌患者,化疗策略:单药:培美曲塞500mg/m2,第1天静脉滴注,每3周重复。联合用药:培美曲塞500mg/m2第1天+卡铂300mg/m2第1天或培美曲塞500mg/m2第1天+顺铂25mg/m2第1~3天,均为每3周重复。结果在27例患者中,无完全缓解患者,部分缓解3例,客观有效率(11.1%),疾病控制率62.9%。结论培美曲塞治疗化疗失败的非小细胞肺癌疗效确切且可耐受。
|
关 键 词: | 培美曲塞 非小细胞肺癌 化学疗法 |
Clinical experience of pemetrexed in patients with locally advanced or metastatic non-sma ll cell lung cancer |
| |
Institution: | WEI Ling,SUN San-yuan,YU Da-hai,et al.(The Central Hospital of Xuzhou,Xuzhou,Jiangsu 221009,China ) |
| |
Abstract: | Objective To observe the safety and efficacy of pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer(NSCLC) after previous chemotherapy.Methods A total of 27 patients with pathologically-confirmed NSCLC were enrolled in this study,Single agent regimen: patients received pemetrexed 500mg/m2 on day 1,by intravenous infusion,with every 21 days.Combination regimen: patients received pemetrexed 500mg/m2 on day 1 and carboplatin 300mg/m2 on day 2 or cisplatin 25mg/m2 on day1~3 by intravenous infusion,with 21 days as one cycle.All patients who received 2 or more cycles could be evaluated.Results 27 patients were evaluable for response and toxicity.The objective response rate was 11.1%(including 0 CR,2 PR).The disease control rate was 62.9%.The common adverse effects were bone marrow suppression and gast rointestinal toxicity.Cnoclusion Pemetrexed is effective and safe in treating patientswith locally advanced ormetastatic NSCLC after failure of previous chemotherapy |
| |
Keywords: | pemetrexed non-small cell lung cancer chemotherapy |
本文献已被 维普 万方数据 等数据库收录! |
|